Four more failed tiragolumab trials, including Imbrave-152, will feature.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.

The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.

While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.

The company will be the first to take a FcRH5-targeting project into phase 3.